🎙️Episode 8: c-Met Targeted Therapy in Lung Cancer: insights from the LUMINOSITY Trial 🎙️ скачать в хорошем качестве

🎙️Episode 8: c-Met Targeted Therapy in Lung Cancer: insights from the LUMINOSITY Trial 🎙️

In this episode, Dr. Pidugu and host Christina break down the pivotal LUMINOSITY trial, a phase II study exploring the use of telisotuzumab vedotin (Teliso-V) in advanced nonsquamous, EGFR-wildtype non-small cell lung cancer (NSCLC) with c-Met protein overexpression. 🧬 What You’ll Learn in This Episode: The clinical significance of c-Met protein overexpression in NSCLC How Teliso-V, an antibody-drug conjugate (ADC), targets cancer cells Design and patient cohorts of the LUMINOSITY phase II trial Key efficacy outcomes including response rates, PFS, OS, and biomarker correlations Safety profile and adverse events such as interstitial lung disease Limitations of the trial and the need for a phase III comparator Insights into the ongoing TeliMET NSCLC-01 global phase III trial FDA's accelerated approval of Teliso-V on May 14, 2025 📊 Whether you're an oncologist, researcher, patient advocate, or just passionate about cancer research, this episode will give you valuable insights into the evolving treatment landscape of NSCLC. 🔔 Subscribe for more episodes on the latest clinical trials and cancer care advances. 📢 Let’s connect: 👍 Like, 💬 Comment, 🔁 Share with your network, and ✅ Subscribe to stay updated! 🎧 Disclaimer: The views expressed are Dr. Pidugu’s personal opinions and are for educational purposes only. Please consult a healthcare provider for medical advice.